NCT04294875

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject With Locally Advanced or Metastatic Solid Malignancies

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: J Ints Bio · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with Locally Advanced or Metastatic Solid Malignancies Phase I. Advanced or metastatic solid malignancy First in Human. HSP90 inhibitor Multi-center clinical trials. Open label. To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640

Detailed description

Classical 3+3 design to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640 . Up to 9 times of administration, Oral suspension, once every 3rd day.

Conditions

• Advanced Solid Tumor
• Metastatic Solid Tumor

Interventions

Type	Name	Description
DRUG	MPT0B640	PO, every 3 days. dose escalation per MTD

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2020-03-04
• Last updated: 2024-03-06

Regulatory

• FDA-regulated drug study